<DOC>
	<DOCNO>NCT00250640</DOCNO>
	<brief_summary>This observational study monitor continue effectiveness Ventavis ( inhale iloprost ) long-term . The study observe effect safety Ventavis inhalation therapy least 2 year 4 year . A total 54 patient around 30 study site Europe include study . This observational study collect information patient receive medication already available prescription participate country . Ventavis use treat moderate case primary pulmonary hypertension .</brief_summary>
	<brief_title>Observation Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety Efficacy 4 Years</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>The treat physician chosen Ventavis suitable longterm treatment patient Patient primary pulmonary hypertension ( i.e . Idiopathic Pulmonary Arterial Hypertension Familial Pulmonary Arterial Hypertension ) classify NYHA functional class III ( NYHA = New York Heart Association ) No prior treatment Ventavis active treatment primary pulmonary hypertension within 6 week date study inclusion ( unless otherwise advise Bayer Schering Pharma ) Any condition prevents participation study , include pregnancy contraindication Ventavis treatment ( list current Ventavis Summary Product Characteristics patient package insert )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Primary Pulmonary hypertension</keyword>
</DOC>